Abstract 298P
Background
Adenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer that is characterized by more favorable outcomes than extramammary ACC. Its rarity makes the establishment of standardized treatment protocols challenging. This study aimed to develop a machine learning (ML)-based prognostic model that improves the accuracy of survival rate predictions for patients with ACC.
Methods
The SEER database provided the data used for this study’s analysis (2000–2020). Patients who met any of the following criteria were excluded: diagnosis not confirmed by histology, previous history of cancer or other concurrent malignancies, or unknown data. To identify prognostic variables, we conducted Cox regression and constructed prognostic models using five ML algorithms to predict the 5-year survival. Patient records were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
The study population comprised 1212 patients. The median patient age was 60 years, and the median tumor size was 1.9 cm. The largest racial group was white (79.5 %). Furthermore, most cases were localized (95.1%), T1 (56.2%), and N0(96.4%). The most common type of surgery performed was partial mastectomy (74.8%). Analysis of the therapeutic options revealed significantly different survival rates. While surgery + RT had a 94.9% overall 5-year survival rate, surgery alone had a rate of 91%. For surgery + CTX, the survival rate was 83.5% and 80.1% for surgery + CTX + RT. The corresponding cancer specific survival rates were 68.5%, 63.5%, 75%, and 70.8%, respectively. The ML models demonstrated strong predictive capabilities, with random forest classifier performing the best. ML identified that the most contributing factors were age, followed by the N component of the AJCC stage and ER status.
Conclusions
ML approaches provide superior predictive performance compared with traditional statistical methods. The developed models can significantly aid personalized treatment planning and improve the clinical outcomes of patients with ACC.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
354P - Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer
Presenter: Lars Anders
Session: Poster session 14
355P - EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study
Presenter: Soraia Lobo-Martins
Session: Poster session 14
356P - Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim results of the PERFORM study
Presenter: Georg Pfeiler
Session: Poster session 14
358P - Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa
Presenter: Tanja Fehm
Session: Poster session 14
359P - Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
Presenter: Takahiro Nakayama
Session: Poster session 14
360P - Identification of circulating immune factors as predictive biomarkers of CDK4/6i treatment efficacy in advanced breast cancer
Presenter: Sara Cabrero-de las Heras
Session: Poster session 14
361P - PALVEN: A phase Ib study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
Presenter: Christine Muttiah
Session: Poster session 14
362P - Dose reductions due to treatment-related side effects and survival outcomes in breast cancer patients treated with CDK4/6 Inhibitors
Presenter: Pinar Kubilay Tolunay
Session: Poster session 14
363P - Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer
Presenter: Sanne Buijs
Session: Poster session 14